Lauri Lehtimaki
Overview
Explore the profile of Lauri Lehtimaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
1262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buchheit K, Shaw D, Chupp G, Lehtimaki L, Heffler E, Finney-Hayward T, et al.
Allergy
. 2024 Oct;
79(10):2662-2679.
PMID: 39359069
Interleukin (IL)-5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its...
12.
Ojanpera L, Lehtimaki L, Huhtala H, Csonka P
Pediatr Pulmonol
. 2024 Sep;
60(1):e27300.
PMID: 39347594
Background: There is a scarcity of high-quality research on the efficient delivery of inhaled corticosteroids using valved holding chambers (VHCs) in children. Methods: The delivered dose (DD) of fluticasone from...
13.
Vartiainen V, Woodcock A, Wilkinson A, Janson C, Bjornsdottir U, Haahtela T, et al.
BMJ Open Respir Res
. 2024 Sep;
11(1).
PMID: 39222967
Introduction: Both physicians and patients are increasingly aware of the environmental impacts of medication. The shift of treatment paradigm towards MART-treatment (Maintenance and Reliever Therapy) in asthma affects the treatment-related...
14.
Persson J, Aakko J, Kaijala S, Lassenius M, Viinanen A, Kankaanranta H, et al.
J Asthma Allergy
. 2024 Jul;
17:681-691.
PMID: 39050030
Purpose: Patients with asthma and low levels of type 2 inflammatory biomarkers (T2 low) have limited effective treatment options. Such biomarkers include eg blood eosinophils (b-eos) and fractional exhaled nitric...
15.
Karjalainen J, Vartiainen V, Tikkakoski A, Malmberg L, Vuotari L, Lahelma S, et al.
Respir Med
. 2024 Jun;
231:107715.
PMID: 38925045
No abstract available.
16.
Denton E, Hew M, Peters M, Upham J, Bulathsinhala L, Tran T, et al.
Allergy
. 2024 Jun;
79(10):2700-2716.
PMID: 38923444
Background: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence,...
17.
Csonka L, Tikkakoski A, Vuotari L, Karjalainen J, Lehtimaki L
Clin Physiol Funct Imaging
. 2024 Jun;
44(6):447-453.
PMID: 38923340
Diagnosis of asthma can be confirmed based on variability in peak expiratory flow (PEF) or changes in forced expiratory volume in 1 s (FEV) measured with spirometry. Our aim was...
18.
Karjalainen J, Vartiainen V, Tikkakoski A, Malmberg L, Vuotari L, Lahelma S, et al.
Respir Med
. 2024 Jun;
230:107693.
PMID: 38851404
Background: Salbutamol is a cornerstone for relieving acute asthma symptoms, typically administered through a pressurized metered-dose inhaler (pMDI). Dry powder inhalers (DPIs) offer an alternative, but concerns exist whether DPIs...
19.
Tikkakoski A, Reini M, Sipila K, Kivisto J, Karjalainen J, Kahonen M, et al.
Acta Paediatr
. 2024 May;
113(8):1942-1948.
PMID: 38780114
Aim: Exercise test outdoors is widely used to diagnose asthma in children, but it is unclear how much outdoor air factors affect the results. Methods: We analysed 321 outdoor exercise...
20.
Scelo G, Tran T, Le T, Fageras M, Dorscheid D, Busby J, et al.
J Allergy Clin Immunol Pract
. 2024 May;
12(9):2347-2361.
PMID: 38768896
Background: Biologic effectiveness is often assessed as response, a term that eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging. Objective: To explore definitions of...